(e) and (f) The special team calculated the amount recoverable from the company after verifying the data submitted by the company.

Exemption from price control of Isoxuprine range formulations

1393. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3283 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) what was the market share taken by Kelkar Committee of leader and follower formulators of Isoxuprine Flucinolone Acetonide, Polymixin-B-Sulphate Glipizide, Phenformin Hcl and Chlorprepamide while considering these drugs for identification for price control;

(b) what was the sales turn over of each of these drugs during 1986 taken on record by Kelkar Committee;

(c) whether it is a fact that these drugs were exempted from price control on the recommendations of Kelkar Committee;

(d) if so, what was the exclusion criteria fulfilled by each of these drugs;

(e) whether it is a fact that there are less than 20 formulation packs based on these drugs marketed by two leading companies of each; and

(f) what was the old and present prices of each?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a), (b) and (d) These details have not been indicated in the report submitted by the Kelkar Committee. Various representations received against the recommendations of the Kelkar Committee were forwarded to the Committee and the Supplementary report submitted by them is under examination.

(c) Yes, Sir.

(e) and (f) Complete details of various formulations based on these bulk drugs are not available.

Production of Avil, Baralgon, Daonil and Lasix

1394. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3631 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) what was the production of each packs and strength of Avil, Baralgon, Daonil and Lasix year wise on which the amount has been recovered;

(b) whether it is a fact that the information in regard to production of these as well as the rate of recovery, the price charged and approved prices are available with the committee who assessed the amount due under DPEA; and

(c) if so, what was the approved prices of each pack of medicines, prices charged by the company, production of each and what was the recovery rate taken by the committee for each on which amount was assessed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The required details to the extent available would be collected and laid on the Table of the House.

Recovery of DPEA dues

1395. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state

(a) what is the total amount recovered under para 7(2) from drug

companies from 1st January, 1988 to 31st October, 1988 under Drug Prices Equalisation Account;

(b) what are the names of the companies and the amount recovered from each;

(c) the names of the companies in whose favour amount under Para 7(2) has been finalised during 1988 upto 31st october but recovery is yet to be initiated;

(d) whether it is a fact that amounts in a number of cases have already been finalised from 1981 onward and communicated to companies but amounts are still to be recovered;

(e) if so, date of finalisation and issuance of communication in each case; and

(f) what steps have been taken to recover that amount and what is the legal position of realisation of interest from due date?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) No amount has been recovered under para 7(2) of DPCO 1979 from drug companies between 1st January, 1988 and 31st october, 1988.

(b) Does not arise.

(c) to (e) The information, to the extent available, is given in the enclosed statement (*See* below). These amounts were assessed between 1984 and 1987 and are disputed by the drug companies.

(f) Necessary action under the process of law would be taken.

Statement

Details of Tentative Amounts assessed under para 7(2) of DPCO, 1979

Sl. No.	Name of the Company	Tentative Amount Assessed (Rs./Ps.)
	Rifampicin	
1.	Biochem Pharmaceuticals	34,27,875.95
2.	Lyka Labs	57,56,747.72
3.	Astra IDL Ltd.	24,10,758.96
4.	Micro Labs.	2,23,725.95
5.	Themis Chemicals Ltd.	36,30,838.00
6.	Alembic Chemicals Labs.	38,72,747.98
7.	Bombay Drug House	1,73,061.00
8.	Pharmed Pvt. Ltd.	68,00,776.80
9.	Dolphin Labs.	18,10,988.20
10.	Albert David Ltd.	3,91,419.00
11.	Pharmaceuticals & Chemicals Ltd.	87,99,326.50
12.	Cadila Labs. P. Ltd.	76,52,433.00
13.	Sarabhai Chemicals	4,13,986.48
14.	Lupin Labs.	2,15,89,000.00
15.	Ranbaxy Labs.	47,77,652.40
16.	Wallace Pharmaceuticals	2,82,071.00
17.	Ethico Drug & Chemical Mfg. Co.	1,40,97,889.00
	Diphyridamol	
1.	M/s. German Remedies	59,95,039.00
	Gentamycin	
1.	M/s. Fulford I Ltd. (Court case)	194.62 lacs
2.	M/s. Biochem Pharma Ltd.	33.88 lacs
3.	M/s. Lyka Labs Ltd.	27.47 lacs

Price approval of Avil Baralgon, Lasix and Daonil

1396. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3631 given in the Rajya